CD274 and mucosal melanoma: One study that investigated the outcomes of both mucosal and acral melanoma treatment with PDL-1 inhibitors showed an 11.5% response rate to treatment.[9] D’angelo et al examined the efficacy and safety of nivolumab alone and in combination with ipilimumab in patients with mucosal melanoma.